KY1101

KY1101 is a small molecule nonsteroidal anti-inflammatory drug (NSAID) currently in preclinical development by KYDES Pharmaceuticals. It is specifically designed as a topical formulation for the localized treatment of arthritis, joint pain, and inflammation. As an NSAID, KY1101 is intended to provide therapeutic relief by inhibiting cyclooxygenase (COX) enzymes, which are responsible for the synthesis of pro-inflammatory prostaglandins. This topical delivery approach aims to concentrate the drug's anti-inflammatory and analgesic effects at the site of application, potentially offering a safer alternative to oral NSAIDs by reducing systemic exposure and minimizing common side effects such as gastrointestinal irritation.